Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

Not Applicable

Terminated

• Conditions: Uterine Cervical Neoplasm
• Interventions: Procedure: Colposcopy/biopsy

• Registration Number: NCT03020121
• Lead Sponsor: Becton, Dickinson and Company

Brief Summary

The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from Liquid-based cytology media diluted in HPV diluent to adjudicated histology results from biopsy.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11
• Study First Submitted: 2017-01-11
• Study First Submitted QC: 2017-01-12
• Study First Posted: 2017-01-13
• Primary Completion: 2017-05
• Study Completion: 2017-05
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-29
• Last Update Posted: 2018-01-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 28

Inclusion Criteria

• Females who are greater than or equal to 21 years of age,
• Subjects with a ASCUS (Atypical Squamous Cells - Undetermined Significance) cytology result,
• Females who provide informed consent

Read More

Exclusion Criteria

• Known pregnant
• Prior complete or partial hysterectomy involving removal of cervix
• Conization, LEEP, cervical laser surgery or cryosurgery on the cervix has been performed in the last twelve months
• Colposcopy clinic referral patients

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BD HPV assay on Viper LT	Colposcopy/biopsy	The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects.

Primary Outcome Measures

Name	Time	Method
Sensitivity	18 months	Sensitivity of the BD HPV Assay for the detection of cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN). Sensitivity is calculated: Number of subjects with a positive BD HPV test with adjudicated histology results of CIN2 or greater divided by the total number of subjects with adjudicated histology results of CIN2 or greater. Similar for CIN3 or greater.
Specificity	18 months	Specificity of the BD HPV Assay for detecting cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN). Specificity is calculated: Number of subjects with a negative BD HPV test with adjudicated histology results of less than CIN2 divided by the total number of subjects with adjudicated histology results of less than CIN2. Similar for CIN3 or greater.
PositivePredictive Value	18 months	Positive Predictive Value (PPV) of the BD HPV Assay for detecting cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN). Positive Predictive Value is calculated: Number of subjects with a positive result for the BD HPV test and adjudicated histology results of CIN2 or greater divided by the total number of subjects with positive result for the BD HPV test. Similar for CIN3 or greater.
Negative Predictive Value	18 Months	Negative Predictive Value (NPV) of the BD HPV Assay for detecting cervical disease as defined by Cervical Intraepithelial Neoplasia (CIN). Negative Predictive Value is calculated: Number of subjects with a negative result for the BD HPV test and histology results less than CIN2 divided by the total number of subjects with negative results for the BD HPV test. Similar for CIN3 or greater.
Likelyhood ratio	18 months	Likelihood ratio for the detection of cervical disease as defined by cervical intraepithelial neoplasia (CIN). The likelihood ratio for each BD HPV test outcome summarizes how many times more (or less) likely subjects with the disease (e.g. CIN2 or greater and CIN3 or greater) are to have that particular HPV test outcome than subjects without the disease.
Absolute Risk	18 Months	Absolute risk for the detection of cervical disease as defined by cervical intraepithelial neoplasia (CIN). The Absolute Risk (AR) of the disease(e.g., CIN2 or greater and CIN3 or greater) for each BD HPV test outcome is the probability of the disease for that particular BD HPV test outcome.
Relative Risk	18 Months	Relative Risk of the detection of cervical disease as defined by cervical intraepithelial neoplasia (CIN). Relative Risk is the ratio between two different absolute risks. The relative risk of having a disease (e.g., CIN2 or greater and CIN3 or greater), will be evaluated to compare two different BD HPV Assay test outcomes.
Positive Percent Agreement	18 Months	Positive percent agreement of the BD HPV Assay as compared to a composite HPV comparator incorporating results for the Digene Hybrid Capture 2 (HC2) HPV test and PCR/Sequencing on both strands of the PCR amplicon (bidirectional sequencing). Positive percent agreement is calculated: Number of subjects with a positive BD HPV test with composite comparator positive divided by the total number of subjects with composite comparator positive.
Negative PercentAgreement	18 months	Negative percent agreement of the BD HPV Assay as compared to a composite HPV comparator incorporating results for the Digene HC2 HPV test and Polymerase Chain Reaction (PCR)/Sequencing on both strands of the PCR amplicon (bidirectional sequencing). Negative percent agreement is calculated: Number of subjects with a negative BD HPV test with composite comparator negative divided by the total number of subjects with composite comparator negative.
Non reportable rate	18 months	.Non-reportable rate of BD HPV test. Non-reportable rate is calculated as the number of non-reportable BD HPV test results divided by the total number of BD HPV test results

Trial Locations

Locations (12)

American Pathology Partners Inc.; 🇺🇸 Denver, Colorado, United States

BioVision; 🇨🇦 Outremont, Quebec, Canada

Comprehensive Clinical Trials, LLC; 🇺🇸 West Palm Beach, Florida, United States

Indiana University; 🇺🇸 Indianapolis, Indiana, United States

Sidney & Lois Eskenazi Hospital; 🇺🇸 Indianapolis, Indiana, United States

Center for Disease Detection; 🇺🇸 San Antonio, Texas, United States

Planned Parenthood of the Rocky Mountains; 🇺🇸 Denver, Colorado, United States

Transgenomics; 🇺🇸 Omaha, Nebraska, United States

Tricore Reference Lab; 🇺🇸 Albuquerque, New Mexico, United States

Research Pathology Associates, LLC; 🇺🇸 Irvington, New York, United States

Research Pathology Associates; 🇺🇸 Charlotte, North Carolina, United States

Southwest Womens Health; 🇺🇸 Albuquerque, New Mexico, United States